Beyond Major Pathologic Response in Lung Cancer: Biomarkers Predict Outcomes.
Where this comes from
- Record sourced from PubMed, PMID 42752583.
- Also identified by DOI 10.1158/1078-0432.CCR-26-2536.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neoadjuvant chemoimmunotherapy improves outcomes in resectable non-small cell lung cancer, yet pathologic response incompletely predicts durability of benefit. Spatial profiling using resected tumors and lymph nodes revealed distinct immune subtypes and identified a gene signature associated with improved outcomes, providing a framework for biomarker-guided treatment selection and prospective validation.